Shares of Edwards Lifesciences Corporation (NYSE:EW – Get Free Report) have been assigned an average rating of “Moderate Buy” from the twenty-seven research firms that are currently covering the company, MarketBeat.com reports. Eight analysts have rated the stock with a hold rating, sixteen have given a buy rating and three have assigned a strong buy rating to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $95.9565.
EW has been the topic of several recent analyst reports. Evercore reissued an “outperform” rating and issued a $93.00 price target on shares of Edwards Lifesciences in a research note on Friday, April 24th. Mizuho set a $95.00 target price on Edwards Lifesciences and gave the stock an “outperform” rating in a research report on Monday, April 13th. Barclays reaffirmed an “overweight” rating and set a $110.00 target price (up from $104.00) on shares of Edwards Lifesciences in a research report on Monday, April 27th. BTIG Research upped their target price on Edwards Lifesciences from $98.00 to $100.00 and gave the stock a “buy” rating in a research report on Friday, April 24th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Edwards Lifesciences in a research report on Monday, April 20th.
Check Out Our Latest Stock Report on EW
Insider Buying and Selling
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in the company. Brighton Jones LLC bought a new position in Edwards Lifesciences in the 4th quarter worth about $266,000. NewEdge Advisors LLC boosted its stake in Edwards Lifesciences by 8.1% in the 2nd quarter. NewEdge Advisors LLC now owns 35,637 shares of the medical research company’s stock worth $2,787,000 after purchasing an additional 2,665 shares during the period. Sei Investments Co. boosted its stake in Edwards Lifesciences by 16.7% in the 2nd quarter. Sei Investments Co. now owns 412,808 shares of the medical research company’s stock worth $32,285,000 after purchasing an additional 58,988 shares during the period. Squarepoint Ops LLC boosted its stake in Edwards Lifesciences by 277.7% in the 2nd quarter. Squarepoint Ops LLC now owns 69,263 shares of the medical research company’s stock worth $5,417,000 after purchasing an additional 50,924 shares during the period. Finally, Treasurer of the State of North Carolina boosted its stake in Edwards Lifesciences by 0.4% in the 2nd quarter. Treasurer of the State of North Carolina now owns 268,860 shares of the medical research company’s stock worth $21,028,000 after purchasing an additional 1,065 shares during the period. Institutional investors own 79.46% of the company’s stock.
Edwards Lifesciences Stock Performance
NYSE:EW opened at $89.56 on Thursday. The stock has a market cap of $51.57 billion, a P/E ratio of 47.64, a price-to-earnings-growth ratio of 2.18 and a beta of 0.87. The company has a current ratio of 4.42, a quick ratio of 3.63 and a debt-to-equity ratio of 0.06. The stock’s 50-day moving average is $83.93 and its 200-day moving average is $83.18. Edwards Lifesciences has a 1-year low of $72.30 and a 1-year high of $90.99.
Edwards Lifesciences (NYSE:EW – Get Free Report) last announced its earnings results on Thursday, April 23rd. The medical research company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.73 by $0.05. Edwards Lifesciences had a return on equity of 15.19% and a net margin of 17.39%.The business had revenue of $1.65 billion for the quarter, compared to analysts’ expectations of $1.60 billion. During the same period in the prior year, the business posted $0.64 earnings per share. The firm’s revenue was up 16.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. Equities research analysts anticipate that Edwards Lifesciences will post 3 earnings per share for the current year.
Edwards Lifesciences Company Profile
Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.
In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.
Featured Stories
- Five stocks we like better than Edwards Lifesciences
- Why KB Home Could Reward Patient Investors Later
- Meta’s Internal Turmoil: Morale Nears 20-Year Low at the Wrong Time
- Tesla’s New NHTSA Probe Lands at the Worst Possible Time
- Nano Nuclear’s AI Data Center Deal Puts the Stock Back in Focus
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.
